Ingenol 3,20-dibenzoate
(Synonyms: 巨大戟醇-3,20-二苯甲酸酯) 目录号 : GC61776Ingenol3,20-dibenzoate是一种有效的蛋白激酶C(PKC)亚型选择性激动剂。Ingenol3,20-dibenzoate诱导nPKC-delta、-epsilon和-theta和PKC-mu从胞质部分选择性转移到颗粒组分,并通过从头合成大分子诱导形态上典型的凋亡(apoptosis)。Ingenol3,20-dibenzoate可促进NK细胞产生IFN-γ和脱颗粒,尤其是当NSCLC细胞刺激NK细胞时。
Cas No.:59086-90-7
Sample solution is provided at 25 µL, 10mM.
Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].
Ingenol 3,20-dibenzoate (0-10000 nM; 4 hours) enhanced NK cells (stimulated by A549 cells and H1299 cells) degranulation[2].Ingenol 3,20-dibenzoate (0.001-10 μg/ml) dose dependently promoted UT-7/EPO cell proliferation with an EC50 of 0.27 μg/ml (485 nM)[3].
Ingenol 3,20-dibenzoate (20 μg/mouse; i.p.; on days 3, 7, and 11) lessens the anemia induced by 5-fluorouracil in an in vivo mouse model[3]. Animal Model: Male C57BL/6 mice (8-12 weeks old)[3]
[1]. Asada A, et al. Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem. 1998;273(43):28392-28398. [2]. Gong C, et al. Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Mol Immunol. 2017;83:23-32. [3]. Oh JG, et al. Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses. Mol Pharmacol. 2015;88(2):392-400.
Cas No. | 59086-90-7 | SDF | |
别名 | 巨大戟醇-3,20-二苯甲酸酯 | ||
Canonical SMILES | O[C@]([C@H]1OC(C2=CC=CC=C2)=O)([C@@H](C(COC(C3=CC=CC=C3)=O)=C4)O)[C@]([C@@H]5C)(C=C1C)C([C@H]4[C@@](C(C)6C)([H])[C@@]6([H])C5)=O | ||
分子式 | C34H36O7 | 分子量 | 556.65 |
溶解度 | DMSO : 100 mg/mL (179.65 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7965 mL | 8.9823 mL | 17.9646 mL |
5 mM | 0.3593 mL | 1.7965 mL | 3.5929 mL |
10 mM | 0.1796 mL | 0.8982 mL | 1.7965 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet